David Brown, MD
Sports Medicine · Houston, TXNPI 1437670460
Payments from drug & device makers
What this record shows
This record is dominated by grants: $20,000 of the $26,758 with a category attached, or 74.7%. Arthrex accounts for 84.8% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2023 at $22,196 and has fallen 92.6% since, to $1,635 in 2025.
Across 61 payments — averaging $438.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$23K
- Medinc Of Texas$3K
- Stryker$666
- Vericel Corporation$115
- Smith+Nephew$39
- Bioventus LLC$17
- plus $15 from 1 others
Across 65 payments — averaging $13,744 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$893K
What the payments were for
- Grants$20,00075%
- Travel & lodging$3,61614%
- Food & beverage$1,9427%
- Education$1,2004%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 32 | $22,685 |
| Medinc Of Texas | 16 | $3,220 |
| Stryker | 8 | $666 |
| Vericel Corporation | 1 | $115 |
| Smith+Nephew | 2 | $39 |
| Bioventus LLC | 1 | $17 |
| Nalu Medical, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,758 in reported general payments places this provider in the 85th percentile of 437 sports medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 27 | $932 |
| Oxycodone Hcl | 55 | $357 |
| Meloxicam | 76 | $207 |
| Ibuprofen | 31 | $182 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $102 |
| Tramadol Hcl | 16 | $41 |
| Ondansetron Hcl | 22 | $27 |
Paid to pharmacies, not to this prescriber.
Other sports medicine in Houston
- Walter LoweHouston$1.4M
- James GregoryHouston$565K
- Robert FullickHouston$137K
- Patrick McCullochHouston$136K
- Joshua HarrisHouston$109K
- Mark AdickesHouston$35K
- Mufaddal GomberaHouston$33K
- Robert FlanneryHouston$27K
- Ankur MehtaHouston$26K
- Thomas DeberardinoSan Antonio$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.